Hi Xavier...
What impressed me was the fact that MCAR is the only company treating incontinence without drugs or surgery, and with virtually no competition to speak of, the company could easily be a take over target. Consider the fact that with MCAR's system, people will no longer need adults diapers. Imagine what the likes of Proctor & Gamble and Kimberly Clark, whose adult diaper sales bring in around $2 billion annually, are going to think when MedCare makes their hugely profitable diaper business obsolete. What are the Boston Scientifics and the other vendors of surgical paraphenalia going to do when their patients don't require costly surgical procedures? Surgeries are not only expensive (over $10,000 a pop), but are risky for the patients - with a 53% (according to US Dept Health) complication rate within a couple of years. Compared to drugs or diapers, MCAR's system seems a god send.
I did a great deal of research on the area before I bought MCAR ($8.125), with no competition in a $16 billion-plus market (diapers, surgeries, etc.) their future in the Urology field is assured.
Forget all those hyped-up mining stocks or some super-duper gizmo deal that you see touted on the Internet. Research MCAR yourself by calling the company directly at 800-611-3388 or visit their web site at www.medcareonline.com. I discovered that MCAR is an exciting ground floor opportunity, that is yet undiscovered by most of the investment world. This stock may well be the next Amgen or Genetech once the word gets out - - which I think will be sooner than most people think.
I understand that MCAR has made a successful application to be listed on the NASDAQ Small Cap <unconfirmed internet rumor!> and this will no doubt get the interest of the big wire house analysts - most of who are restricted from recommending BB stocks.
Good luck and good investing - and do your homework! |
